Mark Purcell
Stock Analyst at Morgan Stanley
(1.78)
# 1,977
Out of 4,435 analysts
5
Total ratings
100%
Success rate
20.59%
Average return
Main Sectors:
Top Industries:
5 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NVS Novartis AG | Initiates: Equal-Weight | $114 | $103.13 | +10.54% | 1 | Jan 23, 2024 | |
| SNY Sanofi | Initiates: Equal-Weight | $55 | $49.03 | +12.18% | 1 | Jan 23, 2024 | |
| GSK GSK | Initiates: Equal-Weight | $44 | $44.77 | -1.72% | 1 | Jan 23, 2024 | |
| AZN AstraZeneca | Initiates: Overweight | $85 | $78.02 | +8.95% | 1 | Jan 23, 2024 | |
| NVO Novo Nordisk | Initiates: Overweight | $120 | $135.28 | -11.30% | 1 | Jan 23, 2024 |
Novartis AG
Jan 23, 2024
Initiates: Equal-Weight
Price Target: $114
Current: $103.13
Upside: +10.54%
Sanofi
Jan 23, 2024
Initiates: Equal-Weight
Price Target: $55
Current: $49.03
Upside: +12.18%
GSK
Jan 23, 2024
Initiates: Equal-Weight
Price Target: $44
Current: $44.77
Upside: -1.72%
AstraZeneca
Jan 23, 2024
Initiates: Overweight
Price Target: $85
Current: $78.02
Upside: +8.95%
Novo Nordisk
Jan 23, 2024
Initiates: Overweight
Price Target: $120
Current: $135.28
Upside: -11.30%